- AstraZeneca to present new cancer care data at WCLC and ESMO 2024, aiming to revolutionize standards of care.
September 03 2024 06:04:21 UTC– AstraZeneca is set to present groundbreaking data on its innovative cancer treatments at the upcoming World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) 2024. The presentations are expected to highlight significant advances in cancer care, underscoring AstraZeneca’s commitment to improving patient outcomes through novel therapies and advanced diagnostics.
At the ESMO 2024 Presidential Symposium, AstraZeneca will showcase the results from the NIAGARA Phase III trial of Imfinzi (durvalumab). This trial evaluates Imfinzi in combination with neoadjuvant chemotherapy prior to cystectomy, followed by Imfinzi as adjuvant monotherapy, in patients with muscle-invasive bladder cancer.
The findings could mark a pivotal moment in cancer treatment, potentially offering a new standard of care for this patient population. The symposium will also emphasize the trend of novel antibody-drug conjugates (ADCs) progressively replacing traditional systemic chemotherapy.
AstraZeneca will also highlight late-breaking exploratory results at WCLC, showcasing the application of its proprietary computational pathology platform, Quantitative Continuous Scoring (QCS), to tissue samples from the TROPION-Lung01 trial. This presentation will demonstrate the potential of TROP2, as measured by QCS, to serve as a predictive biomarker for datopotamab deruxtecan, a leading candidate in the next wave of immunotherapy agents. The findings could pave the way for more personalized and effective cancer treatments.
Additionally, AstraZeneca will present several studies reinforcing its leadership in bispecific antibodies, designed to target cancer from multiple angles. These presentations will include evaluations of novel treatment regimens in lung and gastric cancers, as well as combination approaches aimed at further improving patient outcomes.
AstraZeneca’s commitment to oncology research continues to drive significant advancements in cancer care. The company’s focus on developing novel therapies, including ADCs and bispecific antibodies, aligns with broader trends in oncology, where precision medicine and combination treatments are becoming increasingly pivotal in the fight against cancer.